Data Provider / Broker · vs · Other / Non-Digital Advertising Relevant
HORNBACH Holding vs Sanofi
Structured technology and market comparison · 2026
Direct Feature Comparison
HORNBACH Holding · vs · SanofiListed European DIY retail and building materials holding group.
Biopharmaceutical company selling medicines, vaccines and consumer health products.
Analyze all overlapping signals and tech stacks for HORNBACH Holding and Sanofi
Compare mutual enterprise clients, monetization models, live market signals, and partner networks directly in the interactive Knowledge Graph.
Comparison Analysis
What is the main difference between HORNBACH Holding and Sanofi?
When comparing HORNBACH Holding and Sanofi, both platforms operate within the Data Provider / Broker and Other / Non-Digital Advertising Relevant ecosystem. HORNBACH Holding is positioned as Listed European DIY retail and building materials holding group, whereas Sanofi focuses on Biopharmaceutical company selling medicines, vaccines and consumer health products. Decision-makers evaluate both solutions when orchestrating their commercial monetization and technology stack.
What are the top alternatives to HORNBACH Holding and Sanofi?
When evaluating HORNBACH Holding and Sanofi, enterprise buyers also consider other platforms in Data Provider / Broker and Other / Non-Digital Advertising Relevant. You can discover the full competitive landscape and evaluate other alternatives by viewing their respective footprint profiles on Polaris7.
Market Signals
Recent Market Signals & Activity: HORNBACH Holding vs Sanofi
Documented market movements, strategic partnerships, product releases, and regulatory developments mapped across Polaris7.
HORNBACH Holding
Recent Signals
- ·Retail-NewsFinancials
Hornbach Q2 Revenue and EBIT Up Significantly
Hornbach Holding AG & Co. KGaA reported preliminary results for the second quarter of fiscal 2026/27, with net revenue rising 7.3% year-over-year to €1.814 billion, driven by robust customer demand and 1.3 additional selling days. Adjusted EBIT increased 12.8% to €124.6 million, with the adjusted EBIT margin improving to nearly 6.9%. For the first half, revenue grew 6.0% to €3.816 billion and adjusted EBIT rose 4.9% to €285.6 million. The company confirmed its full-year guidance, expecting net revenue at or slightly above the prior year's €6.434 billion and adjusted EBIT within a range of plus or minus five percent. Geopolitical risks remain a concern, potentially affecting consumer sentiment, purchasing costs, and logistics. Final half-year figures are due on September 29, 2026.
- Q2 2026/27 net revenue rose 7.3% to €1.814 billion.
- Adjusted EBIT increased 12.8% to €124.6 million in Q2.
- H1 net revenue reached €3.816 billion, up 6.0%.
Sanofi
Recent Signals
- ·SEC APIfinancials
6-K Financial Filing Analysis for Sanofi (2026-08-06)
Sanofi filed a Form 6-K on August 6, 2026, incorporating a press release announcing European Union approval for MenQuadfi. The vaccine has received expanded marketing authorization in the EU for immunization against invasive meningococcal disease in infants starting from six weeks of age. This regulatory milestone expands the target patient demographic for MenQuadfi, bolstering Sanofi Vaccines' pediatric portfolio and competitive standing across European healthcare markets.
- MenQuadfi received EU regulatory approval for protection against invasive meningococcal disease in infants from age six weeks.
- The official press release detailing the approval was issued on August 4, 2026, and submitted via Form 6-K on August 6, 2026.
- ·SEC APIfinancials
6-K Financial Filing Analysis for Sanofi (2026-09-17)
On September 17, 2026, Sanofi submitted a Form 6-K filing with the U.S. Securities and Exchange Commission incorporating a press release dated September 14, 2026. The filing announces a new strategic partnership between Sanofi and Cheplapharm focused on mature medicines. This partnership reflects Sanofi's ongoing portfolio optimization strategy, allowing the company to streamline operations, monetize or efficiently manage established pharmaceutical assets, and reallocate focus and capital toward core growth drivers and innovative pipeline therapies.
- Sanofi entered into a strategic partnership with Cheplapharm focused on its mature medicines portfolio, originally announced via press release on September 14, 2026.
- The Form 6-K regulatory submission was formally executed and signed on September 17, 2026, by Alexandra Roger, Head of Legal Corporate & Finance.
- ·Sanofi
Sanofi and Cheplapharm to create new strategic partnership in mature medicines
Press Release: Sanofi and Cheplapharm to create new strategic partnership in mature medicines
Compare their exact ecosystem overlaps.
Explore all deep relationships in Polaris7. Discover exactly which mutual clients, integrated technologies, and overlapping partners HORNBACH Holding and Sanofi share across the market ecosystem.